Navigation Links
New therapy effectively treats deep vein thrombosis
Date:1/28/2008

OAK BROOK, Ill. A novel treatment for blood clots in the legs appears to be safe and effective, according to a pilot study published in the February issue of Radiology. The study found that injecting or lacing the clot with a fiber-binding thrombolytic agent effectively treats deep vein thrombosis (DVT) and reduces the risk of subsequent recurrence or bleeding.

This treatment regimen is able to clear blood clots rapidly and safely, restoring blood flow in the veins of the lower leg, and the results are durable, said lead author Richard Chang, M.D., chief of the interventional radiology section of the Department of Radiology, Clinical Center, National Institutes of Health (NIH), Bethesda, Md.

DVT is a common and serious health problem in which a blood clot, or thrombus, form in the deep veins, particularly in the lower leg or thigh. Complications occur when the clot breaks off and travels to the lungs, resulting in pulmonary embolism, a potentially fatal condition.

Most patients with DVT are treated solely with anticoagulation therapy (blood thinners) and compression stockings. However, studies have shown that one-third of these patients will suffer from post-thrombotic syndrome, characterized by pain, swelling, or in severe cases by changes in skin color or skin ulceration. Another third are likely to have another clot or pulmonary embolism within five years of their initial DVT.

Treatments with thrombolytic (clot-dissolving) therapy could potentially protect against these occurrences, but can pose a bleeding risk. Therefore, Dr. Chang and colleagues sought to develop a safe, effective and affordable thrombolytic treatment regimen for DVT.

Twenty patients with acute DVT were treated with direct intraclot lacing of the thrombus with a clot-dissolving agent called alteplase and full systemic anticoagulation. Alteplase binds to the clot, so the procedure does not require continuous infusion of the drug, as do some thrombolytic therapies. With this treatment, after lacing one vein segment with alteplase, the interventional radiologist can immediately direct catheters to treat other vein segments to ensure that the entire clot has been adequately treated.

The results of the study showed that blood flow was restored throughout the deep venous system in 16 (80 percent) of the 20 patients during therapy with complete resolution of symptoms in 18 patients (90 percent) after six months of anticoagulation. Alteplase was cleared from the patients circulatory system within two hours of treatment, reducing the risk of subsequent bleeding.

There were no serious complications or bleeding during the treatment, and no cases of post-thrombotic syndrome or recurrent clotting during follow-up of 3.4 years.

With this therapy, pain and swelling resolve rapidly, and, in most cases, the patient is able to resume all normal activity within a week, said the studys co-author, McDonald K. Horne III, M.D., from the hematology section of the Department of Lab Medicine, Clinical Center, NIH.

The authors caution that larger clinical trials are required to further support the efficacy of this promising treatment.


'/>"/>

Contact: Linda Brooks
lbrooks@rsna.org
630-590-7762
Radiological Society of North America
Source:Eurekalert

Related medicine news :

1. Vision restoration therapy shown to improve brain activity in brain injured patients
2. HIV therapy in pregnancy-data support WHO recommendations
3. Family-based treatment more effective than supportive psychotherapy in treating bulimia
4. Trial to Test Gene Therapy for Angina in Women
5. One of the Largest Post-WHI Physician Surveys Shows More Education is Needed: Patient Misinformation About Hormone Therapy Remains High
6. Aromatherapy Gift Line Sheds Humorous Light on Modern Therapy
7. Chemotherapy may be culprit for fatigue in breast cancer survivors
8. Atlanta Falcons Physical Therapy Centers Set to Launch This Fall
9. New Drug No Substitute for Standard Blood-Clot Therapy
10. Stem Cell Therapy Disappoints Against Rare Kidney Ailment
11. Nucletron Announces Management Buy-Out to More Effectively Meet the Demands of Its Customers and the Radiation Therapy Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , ... April 28, 2016 , ... ... today announced it will demonstrate its leading secure mobility workstation suite, SentinelSecure™, at ... Held at Hilton Union Square, this will be MobileIron’s 6th Mobile First Conference ...
(Date:4/28/2016)... ... April 28, 2016 , ... Denise McCormick Baich had written poetry dating back to her childhood, ... much like a tsunami and took on a more spiritual tone. The desire to put ... do more with it than just file it away. Friends would ask her how she ...
(Date:4/28/2016)... ... ... For the 10,000 Americans who turn 65 on any given day, “getting wiser” with ... Now, a new book—Staying Sharp For Dummies (Paper; ISBN: 978-1-119-18779-0; Available Now)—outlines simple things ... from honing your memory and managing stress to eating healthy foods as part of ...
(Date:4/28/2016)... Boston,MA (PRWEB) , ... April 28, 2016 , ... Boston ... U.S Food and Drug Administration (FDA). The treatment consists of the application of Riboflavin, ... of the collagen fibers which in turn strengthens the cornea to slow the progression ...
(Date:4/28/2016)... MA (PRWEB) , ... April 28, 2016 , ... The ... eating patterns based on the latest nutritional science. While there is a lot of ... improve their health, according to the April 2016 issue of Harvard Men's Health ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... Research and Markets has ... Disposables Market 2016-2020"  report to their offering.  ... global anesthesia disposables market is set to ... the period 2016-2020.  Healthcare-acquired infections ... safety. Organizations like the CDC and Public ...
(Date:4/27/2016)... FRANCISCO , April 27, 2016 ... reach over USD 2.14 billion by 2022, according ... Inc.       (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ... technological advancement affecting the efficiency and accuracy delivered ... the persistent demand for novel urinalysis instruments and ...
(Date:4/27/2016)... April 27, 2016 At the ... launch of a Phase 2 clinical study of its ... patients undergoing cochlear implantation (CI) surgery. This large, placebo-controlled, ... Germany and France ... ear at the time of surgery. "Despite advances in ...
Breaking Medicine Technology: